|
1
|
Mendelsohn J and Baselga J: Epidermal
growth factor receptor targeting in cancer. Semin Oncol.
33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Andreyev HJ, Norman AR, Cunningham D,
Oates JR and Clarke PA: Kirsten ras mutations in patients with
colorectal cancer: The multicenter ‘RASCAL’ study. J Natl Cancer
Inst. 90:675–684. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Allegra CJ, Jessup JM, Somerfield MR,
Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF and
Schilsky RL: American Society of Clinical Oncology provisional
clinical opinion: Testing for KRASgene mutations in patients with
metastatic colorectal carcinoma to predict response to
anti-epidermal growth factor receptor monoclonal antibody therapy.
J Clin Oncol. 27:2091–2096. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lièvre A, Bachet JB, Le Corre D, Boige V,
Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al:
KRASmutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006. View Article : Google Scholar
|
|
6
|
Normanno N, Tejpar S, Morgillo F, De Luca
A, Van Cutsem E and Ciardiello F: Implications for KRAS status and
EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol.
6:519–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bardelli A and Siena S: Molecular
mechanisms of resistance to cetuximab and panitumumab in colorectal
cancer. J Clin Oncol. 28:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Amado RG, Wolf M, Peeters M, Van Cutsem E,
Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et
al: Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cavallini A, Valentini AM, Lippolis C,
Campanella D, Guerra V and Caruso ML: KRASgenotyping as biomarker
in colorectal cancer: A comparison of three commercial kits on
histologic material. Anticancer Res. 30:5251–5256. 2010.PubMed/NCBI
|
|
10
|
Malapelle U, Carlomagno C, de Luca C,
Bellevicine C and Troncone G: KRAS testing in metastatic colorectal
carcinoma: Challenges, controversies, breakthroughs and beyond. J
Clin Pathol. 67:1–9. 2014. View Article : Google Scholar
|
|
11
|
Lee S, Brophy VH, Cao J, Velez M, Hoeppner
C, Soviero S and Lawrence HJ: Analytical performance of a PCR assay
for the detection of KRAS mutations (codons 12/13 and 61) in
formalin-fixed paraffin-embedded tissue samples of colorectal
carcinoma. Virchows Arch. 460:141–149. 2012. View Article : Google Scholar :
|
|
12
|
Gonzalez de Castro D, Angulo B, Gomez B,
Mair D, Martinez R, Suarez-Gauthier A, Shieh F, Velez M, Brophy VH,
Lawrence HJ, et al: A comparison of three methods for detecting
KRAS mutations in formalin-fixed colorectal cancer specimens. Br J
Cancer. 107:345–351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tol J, Dijkstra JR, Vink-Börger ME,
Nagtegaal ID, Punt CJ, Van Krieken JH and Ligtenberg MJ: High
sensitivity of both sequencing and real-time PCR analysis of
KRASmutations in colorectal cancer tissue. J Cell Mol Med.
14:2122–2131. 2010. View Article : Google Scholar
|
|
14
|
Chambers PA, Stead LF, Morgan JE, Carr IM,
Sutton KM, Watson CM, Crowe V, Dickinson H, Roberts P, Mulatero C,
et al: Mutation detection by clonal sequencing of PCR amplicons and
grouped read typing is applicable to clinical diagnostics. Hum
Mutat. 34:248–254. 2013. View Article : Google Scholar
|
|
15
|
Ikeda S, Kubota T, Yuki M and Okamoto A:
Exciton-controlled hybridization-sensitive fluorescent probes:
Multicolor detection of nucleic acids. Angew Chem Int Ed Engl.
48:6480–6484. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lezhava A, Ishidao T, Ishizu Y, Naito K,
Hanami T, Katayama A, Kogo Y, Soma T, Ikeda S, Murakami K, et al:
Exciton Primer-mediated SNP detection in SmartAmp2 reactions. Hum
Mutat. 31:208–217. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hanami T, Delobel D, Kanamori H, Tanaka Y,
Kimura Y, Nakasone A, Soma T, Hayashizaki Y, Usui K and Harbers M:
Eprobe mediated real-time PCR monitoring and melting curve
analysis. PLoS One. 8:e709422013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kimura Y, Hanami T, Tanaka Y, de Hoon MJ,
Soma T, Harbers M, Lezhava A, Hayashizaki Y and Usui K: Effect of
thiazole orange doubly labeled thymidine on DNA duplex formation.
Biochemistry. 51:6056–6067. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nagai Y, Miyazawa H, Huqun, Tanaka T,
Udagawa K, Kato M, Fukuyama S, Yokote A, Kobayashi K, Kanazawa M,
et al: Genetic heterogeneity of the epidermal growth factor
receptor in non-small cell lung cancer cell lines revealed by a
rapid and sensitive detection system, the peptide nucleic
acid-locked nucleic acid PCR clamp. Cancer Res. 65:7276–7282. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arcila M, Lau C, Nafa K and Ladanyi M:
Detection of KRAS and BRAFmutations in colorectal carcinoma roles
for high-sensitivity locked nucleic acid-PCR sequencing and
broad-spectrum mass spectrometry genotyping. J Mol Diagn. 13:64–73.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dono M, Massucco C, Chiara S, Sonaglio C,
Mora M, Truini A, Cerruti G, Zoppoli G, Ballestrero A, Truini M, et
al: Low percentage of KRASmutations revealed by locked nucleic acid
polymerase chain reaction: Implications for treatment of metastatic
colorectal cancer. Mol Med. 18:1519–1526. 2012. View Article : Google Scholar
|
|
22
|
Oh JE, Lim HS, An CH, Jeong EG, Han JY,
Lee SH and Yoo NJ: Detection of low-level KRASmutations using
PNA-mediated asymmetric PCR clamping and melting curve analysis
with unlabeled probes. J Mol Diagn. 12:418–424. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Beau-Faller M, Legrain M, Voegeli A-C,
Guérin E, Lavaux T, Ruppert AM, Neuville A, Massard G, Wihlm JM,
Quoix E, et al: Detection of K-Rasmutations in tumour samples of
patients with non-small cell lung cancer using PNA-mediated PCR
clamping. Br J Cancer. 100:985–992. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Däbritz J, Hänfler J, Preston R, Stieler J
and Oettle H: Detection of Ki-ras mutations in tissue and plasma
samples of patients with pancreatic cancer using PNA-mediated PCR
clamping and hybridisation probes. Br J Cancer. 92:405–412.
2005.PubMed/NCBI
|
|
25
|
Araki T, Shimizu K, Nakamura K, Nakamura
T, Mitani Y, Obayashi K, Fujita Y, Kakegawa S, Miyamae Y, Kaira K,
et al: Usefulness of peptide nucleic acid (PNA)-clamp smart
amplification process version 2 (SmartAmp2) for clinical diagnosis
of KRAS codon 12 mutations in lung adenocarcinoma: Comparison of
PNA-clamp SmartAmp2 and PCR-related methods. J Mol Diagn.
12:118–124. 2010. View Article : Google Scholar
|
|
26
|
Tatsumi K, Mitani Y, Watanabe J, Takakura
H, Hoshi K, Kawai Y, Kikuchi T, Kogo Y, Oguchi-Katayama A, Tomaru
Y, et al: Rapid screening assay for KRASmutations by the modified
smart amplification process. J Mol Diagn. 10:520–526. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miyamae Y, Shimizu K, Mitani Y, Araki T,
Kawai Y, Baba M, Kakegawa S, Sugano M, Kaira K, Lezhava A, et al:
Mutation detection of epidermal growth factor receptor and
KRASgenes using the smart amplification process version 2 from
formalin-fixed, paraffin-embedded lung cancer tissue. J Mol Diagn.
12:257–264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Krypuy M, Newnham GM, Thomas DM, Conron M
and Dobrovic A: High resolution melting analysis for the rapid and
sensitive detection of mutations in clinical samples: KRAS codon 12
and 13 mutations in non-small cell lung cancer. BMC Cancer.
6:2952006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tsiatis AC, Norris-Kirby A, Rich RG, Hafez
MJ, Gocke CD, Eshleman JR and Murphy KM: Comparison of Sanger
sequencing, pyrosequencing, and melting curve analysis for the
detection of KRASmutations: Diagnostic and clinical implications. J
Mol Diagn. 12:425–432. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aubin F, Gill S, Burkes R, Colwell B,
Kamel-Reid S, Koski S, Pollett A, Samson B, Tehfe M, Wong R, et al:
Canadian Expert Group consensus recommendations: KRAS testing in
colorectal cancer. Curr Oncol. 18:e180–e184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Blons H, Rouleau E, Charrier N, Chatellier
G, Côté JF, Pages JC, de Fraipont F, Boyer JC, Merlio JP, Morel A,
et al MOKAECM Collaborative Group: Performance and cost efficiency
of KRAS mutation testing for metastatic colorectal cancer in
routine diagnosis: The MOKAECM study, a nationwide experience. PLoS
One. 8:e689452013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ludyga N, Grünwald B, Azimzadeh O, Englert
S, Höfler H, Tapio S and Aubele M: Nucleic acids from long-term
preserved FFPE tissues are suitable for downstream analyses.
Virchows Arch. 460:131–140. 2012. View Article : Google Scholar : PubMed/NCBI
|
